NASDAQ: RVMDW - Revolution Medicines, Inc. Warrant

Rentabilität für sechs Monate: -46.43%
Dividendenrendite: 0.00%

Aktionsplan Revolution Medicines, Inc. Warrant

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Revolution Medicines, Inc. Warrant

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.

weitere details
Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2023-11-17
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.revmed.com
Цена ао 0.0939
Preisänderung pro Tag: -20.13% (0.0939)
Preisänderung pro Woche: -23.23% (0.0977)
Preisänderung pro Monat: -31.88% (0.1101)
Preisänderung über 3 Monate: -70.26% (0.2522)
Preisänderung über sechs Monate: -46.43% (0.14)
Preisänderung pro Jahr: -67.25% (0.229)
Preisänderung seit Jahresbeginn: -76.05% (0.3131)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0 0
Gesamt: 2.5

Effizienz

Name Bedeutung Grad
ROA, % 0 0
ROE, % 0 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA 0 10
Gesamt: 10

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % -74.92 0
Rentabilität Ebitda, % 297 10
Rentabilität EPS, % 175.15 10
Gesamt: 8
Weitere Details

Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Dr. Mark A. Goldsmith Ph.D. CEO, President & Chairman 1962 (63 Jahr)
Mr. Jack Anders Chief Financial Officer 1977 (48 Jahre)
Ms. Margaret A. Horn J.D. Chief Operating Officer 1963 (62 Jahr)
Dr. Stephen M. Kelsey FRC Path., FRCP, M.D. President of Research & Development 1961 (64 Jahr)
Ms. Xiaolin Wang Executive Vice President of Development 1971 (54 Jahr)
Dr. Martin D. Burke M.D., Ph.D. Co-Founder & Chairman of Scientific Advisory Board
Dr. Michael A. Fischbach Ph.D. Academic Co-Founder & Member of Scientific Advisory Board 1981 (44 Jahr)
Dr. Kevan M. Shokat Ph.D. Academic Co-Founder & Member of Scientific Advisory Board
Mr. Walter Reiher Ph.D. Chief Information Officer
Ms. Jan Smith Ph.D. Chief Scientific Officer

Adresse: United States, Redwood City, 700 Saginaw Drive - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.revmed.com